IMI - Innovative Medicines Initiative

IMI is a Joint Technological Initiative (JTI), a public-private partnership involving industry, research community and public authorities to pursue common ambitious research objectives. IMI is a joint undertaking between the EU and the pharmaceutical industry association EFPIA. As the largest JTI, IMI supports collaborative research projects and networks of industrial and academic experts. 

IMI 2 under Horizon 2020

In July 2013, the European Commission released its proposal for the Innovative Medicines Initiative 2 (IMI 2), which will develop next generation vaccines, medicines and treatments, and has to be approved by the European legislator (Parliament and Council).

Horizon 2020 rules will apply to the IMI 2 evaluation process and project management. The total proposed budget is EUR 3.45 billion, with EUR 1.725 billion coming from Horizon 2020 and EUR 1.5 billion contributed by EFPIA (the European Federation of Pharmaceutical Industries and Associations). Other life science industries may contribute additional funding if joining IMI 2 project partners. 

Starting in 2014, IMI 2 will run for 10 years.

The Strategic Research Agenda (SRA), published in March 2014, focuses on delivering "the right prevention and treatment for the right patient at the right time". As a result of an extensive stakeholder consultation process, it will guide IMI 2 projects for the coming years.

Participation in IMI projects

IMI launches a new set of research and/or training projects every year, in order to support prospective, pre-competitive pharmaceutical research and development. Project participants are recruited through open and competitive Calls for research proposals. The selection of the winning proposals is based on independent peer review and concluded by a Grant Agreement and Project Agreement.

Calls 2015

Application submissions for 2017 are now closed.

However, the following topics are under consideration to be included in the next calls :

  • Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s disease (RADAR-AD) 
  • Fairification of IMI and EPPIA data
  • Development of sensitive and validated clinical endpoints in primary Sjögren's syndrome (PSS)
  • European screening centre: unique library for attractive biology
  • Exploitation of IMI project results 

Further information on future topics can be found here.